Document is current

Article History

Received: 13 March 2025

Accepted: 21 October 2025

First Online: 10 December 2025

Declarations

:

: Patients were invited via e-mail and social media advertising, and those who were interested followed the survey link, which directed them to an electronic screening questionnaire, and if eligible, to a subsequent electronic consent form. Consenting participants were then directed to the main questionnaire. All data were captured electronically. The study protocol for the RW population was reviewed and approved by the Salus Institutional Review Board (#IRB00013544; determination date: 16 September 2022). Patients were remunerated for the time spent completing the online survey.

: Not applicable.

: M.A.K. has served as a speaker and/or advisor for AbbVie, Aleafia Health, Allergan, Bausch Health, Biron, Canopy, Eisai, Elvium, Idorsia, Lundbeck, Janssen, Lilly, Novartis, Merck, Otsuka, Pfizer, Purdue, Sante Cannabis, Sunovion, Takeda, and Tilray. He has also supported clinical trials and/or research studies for AbbVie, Aleafia Health, Biohaven, Biron, Canopy, Lundbeck, Janssen, Lilly, Pfizer, and Takeda. A.P.-B. is the director of Innovus Consulting Ltd, which received financial support from Idorsia for work on this study. Innovus Consulting Ltd was paid for the writing of the manuscript. S.H. and M.R. are employees of Evidera, which received financial support from Idorsia (via Innovus) for work on this study.